BioSpace News Archive

Medtronic announced today that its Board of Directors appointed Greg Lewis , Senior Vice President and Chief Financial Officer at Honeywell, to the Board.

Chemomab Therapeutics Ltd. today reported that it presented two scientific posters supporting the clinical rationale for the company’s primary sclerosing cholangitis (PSC) program at EASL 2023, the Annual Congress of the European Association for the Study of the Liver, which took place June 21-24, 2023 in Vienna, Austria.

OpGen, Inc. and OpGen subsidiary, Ares Genetics, which strives to become a leader in bacterial genomics and AI-powered prediction of antimicrobial resistance (AMR), announced today that one of its key patents under opposition has been successfully maintained.

Endo International plc (OTC: ENDPQ) announced today that the first patient has been enrolled in GRASP-DC (Generating Real-world Ambispective data to Study Participant Treatment outcomes for Dupuytren’s Contracture), a non-interventional registry of up to 1,000 patients with Dupuytren’s contracture (DC).

Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a clinical-stage company and leader in cell therapeutics, today announced updated positive interim data from its ongoing Phase 1/2 clinical trial of the Cell Pouch System in patients with type 1 diabetes (T1D) and severe hypoglycemia unawareness.

Agile Therapeutics, Inc. today announced that Twirla will become available to MMCAP Infuse Members effective July 1, 2023.

Benitec Biopharma Inc. today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for BB-301.

Ocean Biomedical, Inc. (NASDAQ: OCEA) announced today that a new, broad U.S. patent for bispecific antibodies targeting chitinase 3-like-1 (CHi3L1) and programmed cell death protein 1 (PD-1), a promising new approach that has emerged from prior breakthrough discoveries that CHi3L1 is a “master regulator” of tumor growth in multiple visceral cancers, has been issued to one of its Scientific Co-founders, Dr. Jack A. Elias, MD.

Corbus Pharmaceuticals Holdings, Inc. today announced that the Company is set to join the Russell Microcap® Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the US market opens today.

Enveric Biosciences today announced the development of an improved formulation of EB-373 designed to enhance the drug product’s scalability, stability, and delivery for ongoing preclinical studies and planned clinical development.